Periodic Reporting for period 1 - MuSiC4Diabetes (Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes)
Reporting period: 2023-10-01 to 2024-09-30
Diabetes patients carry an enormous burden every day. MuSiC4Diabetes will provide a radically new approach for long-term continuous monitoring of insulin-treated persons with diabetes (ITD) moving from a glucose-only to a Multi-Metabolite (MM) monitoring - glucose, lactate and 3 β OH-butyrate (3-ßOHB) paradigm. MM monitoring will also lead to a diabetes therapy breakthrough by algorithmically driving a continuous physiologic insulin delivery by a maintenance-free implanted MEMS pump using the peritoneal route enabling an optimal therapy for subjects with ITD.
In the first year of project activity, an efficient management structure was established and a number of deliverables were created and submitted to the EC. Work on the tasks according to the work plan began; the project is currently on schedule in all work packages.
As part of the portfolio activities, work began on developing a roadmap and strategy for a healthcare continuum together with researchers from the other projects in this call. M4D contributes to the following groups (Knowledge Exchange (PV), Ethics and Regulation (CHUM), IP and Commercialization (EURICE)). Furthermore, M4D coordinates the Technology Transfer (FHG) group. Those roadmaps will be incorporated into a joint strategy paper in autumn 2024.
In the first year of project activity, an efficient management structure was established and a number of deliverables were created and submitted to the EC. Work on the tasks according to the work plan began; the project is currently on schedule in all work packages.
As part of the portfolio activities, work began on developing a roadmap and strategy for a healthcare continuum together with researchers from the other projects in this call. M4D contributes to the following groups (Knowledge Exchange (PV), Ethics and Regulation (CHUM), IP and Commercialization (EURICE)). Furthermore, M4D coordinates the Technology Transfer (FHG) group. Those roadmaps will be incorporated into a joint strategy paper in autumn 2024.
After establishing efficient management structures, the system was designed and specified with the help of the medical partners. These specifications formed the basis of the design and simulation phase, both for the sensor and for the insulin dosing system. An intensive design and simulation phase followed for key components of the system (MEMS micropump, safety valve), which culminated in the start of a clean room run. Regarding the human factor, a survey of various patient groups was carried out and evaluated with regard to the acceptance of an implantable system. Communication and dissimination activities started (e.g. Webpage https://music4diabetes.eu/(opens in new window) LinkedIn).
Our vision is to completely relieve patients of this daily burden with an implantable system: an implantable multi-parameter sensor measures not only the blood sugar level, but also other parameters such as lactate and ketones, which enables much more precise control. An implantable micropump is designed to deliver a highly concentrated insulin in the abdominal cavity, which is an additional advantage over subcutaneous administration. The patient will not notice any of this, the insulin will only be refilled via a port every three months.